Is Accretion Pha. overvalued or undervalued?

As of 18 November 2025, the valuation grade for Accretion Pharmaceuticals has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 12.72, an EV to EBIT of 8.47, and a ROCE of 20.47%.
In comparison to its peers, Accretion Pharmaceuticals stands out with a significantly lower PE ratio than Sun Pharma (36.56) and Divi's Lab (69.17), both of which are considered expensive. Additionally, its EV to EBITDA ratio of 7.92 is more attractive compared to the higher ratios of its peers. The company's recent stock performance has also been notable, with a 1-week return of 29.5%, significantly outperforming the Sensex's return of 0.84%.